で公開中です! 詳しく見る
ABCLのアイコン

AbCellera Biologics

11.80 USD
-0.88
6.94%
終値時点 更新済み 10月16日 16:00 EDT
プレマーケット
時間外取引
11.80
0.00
0%
1日
-6.94%
5日間
-7.16%
1か月
1.11%
3か月
91.56%
6か月
208.09%
年初来
244.02%
1年
102.05%
5年間
-22.77%
10年間
-79.97%
 

概要: AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

従業員数: 562

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 34.8%
ニュートラル 60.9%
ネガティブ 4.3%
ニュートラル
Business Wire
8 日前
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting.
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
ニュートラル
Business Wire
15 日前
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026.
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
ポジティブ
Zacks Investment Research
24 日前
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
ニュートラル
Business Wire
先月
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026.
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
ニュートラル
Business Wire
先月
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026.
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
ポジティブ
Benzinga
先月
What'sGoing On With AbCellera Biologics Stock On Tuesday?
AbCellera Biologics Inc. (NASDAQ:ABCL) stock is trading higher on Tuesday. Year-to-date, the stock has jumped over 250%.
What'sGoing On With AbCellera Biologics Stock On Tuesday?
ポジティブ
Seeking Alpha
2 か月前
Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes
Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.
Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes
ニュートラル
Business Wire
2 か月前
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
ポジティブ
Benzinga
2 か月前
What's Going on With AbCellera Biologics Stock On Wednesday?
AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trading higher on Wednesday following the announcement of positive Phase 2 clinical trial results for ABCL635, a single-dose treatment aimed at alleviating menopausal hot flashes.
What's Going on With AbCellera Biologics Stock On Wednesday?
ニュートラル
Business Wire
2 か月前
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants.
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
価格チャートは Lightweight Charts™ を使用して実装されています